LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

Waystar to Present at Upcoming Investor Conferences

April 30, 2025 | Last Trade: US$40.04 0.58 1.47

LEHI, Utah and LOUISVILLE, Ky., April 30, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins and Chief Financial Officer Steve Oreskovich will speak at two upcoming investor conferences.

Oreskovich will present at the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025, at 8:40 a.m. PT. Hawkins will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3, 2025, at 12 p.m. CT.

Both presentations will stream live on Waystar's Investor Relations website at https://investors.waystar.com/news-events/events. Recordings will be available on the site afterward.

About Waystar

Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.
502-238-9511

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page